Alexander Zhavoronkov

Alex Zhavoronkov.jpg

Chief Executive Officer

 Insilico Medicine, Inc

Alexander Zhavoronkov, PhD, is the Chief Executive Officer of Insilico Medicine, Inc, a Baltimore-based company applying the latest advances in artificial intelligence to drug discovery, biomarker development, and aging research. He holds two Bachelor Degrees from Queen’s University, a Masters in Biotechnology from Johns Hopkins University, and a PhD in Biophysics from the Moscow State University. Alexander is the Chief Scientific Officer of the Biogerontology Research Foundation, a UK-based registered charity supporting aging research worldwide. He is also the director of the International Aging Research Portfolio (IARP) knowledge management project, chief scientist of Youth Laboratories and an adjunct professor at the Moscow Institute of Physics and Technology.

Prior to switching his focus to aging research in 2004, he worked as the director of ATI Technologies, a major Canadian GPU company, and was the co-founder of and CSO of NeuroG, a neuroinformatics company. Alex Zhavoronkov is the author of over 90 research publications in peer-reviewed journals. He wrote several books: “The Ageless Generation: How advances in biomedicine will transform the global economy” (Palgrave Macmillan, 2013) and “Dating AI: A Guide to Falling in Love with Artificial Intelligence” (RE/Search, 2012). Alex is the editor of numerous journals, including aging, Oncotarget: Gerotarget, Frontiers in Genetics, and Frontiers in Molecular Biosciences. He also is co-organizing the annual Aging and Drug Discovery Forum and the annual Artificial Intelligence & Blockchain for Healthcare Forum in Basel, Switzerland, as part of EMBO/Basel Life Congress.